Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | FK506 binding protein 1A, 12kDa | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Trypanosoma brucei | macrophage infectivity potentiator, precursor, putative | FK506 binding protein 1A, 12kDa | 108 aa | 107 aa | 48.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | FK506-binding protein (FKBP)-type peptidyl-prolyl isomerase, putative | 0.0065 | 0.0277 | 0.5 |
Trichomonas vaginalis | immunophilin, putative | 0.0065 | 0.0277 | 0.5 |
Loa Loa (eye worm) | FKBP-type peptidyl-prolyl cis-trans isomerase-12 | 0.0065 | 0.0277 | 0.0277 |
Trypanosoma cruzi | FK506-binding protein (FKBP)-type peptidyl-prolyl isomerase, putative | 0.0065 | 0.0277 | 0.5 |
Trichomonas vaginalis | peptidylprolyl isomerase, putative | 0.0065 | 0.0277 | 0.5 |
Schistosoma mansoni | immunophilin FK506 binding protein FKBP12 | 0.0065 | 0.0277 | 0.0277 |
Echinococcus granulosus | peptidyl prolyl cis trans isomerase FKBP4 | 0.0065 | 0.0277 | 0.0277 |
Trichomonas vaginalis | peptidylprolyl isomerase, putative | 0.0065 | 0.0277 | 0.5 |
Echinococcus granulosus | peptidyl prolyl cis trans isomerase FKBP1A | 0.0065 | 0.0277 | 0.0277 |
Schistosoma mansoni | immunophilin | 0.0065 | 0.0277 | 0.0277 |
Treponema pallidum | peptidyl-prolyl cis-trans isomerase, FKBP-type, 22 kDa (fklB) | 0.0065 | 0.0277 | 0.5 |
Loa Loa (eye worm) | FKBP5 protein | 0.0065 | 0.0277 | 0.0277 |
Echinococcus multilocularis | fk506 binding protein | 0.0065 | 0.0277 | 0.0277 |
Trypanosoma cruzi | peptidyl-prolyl cis-trans isomerase, putative | 0.0065 | 0.0277 | 0.5 |
Entamoeba histolytica | peptidyl-prolyl cis-trans isomerase, FKBP-type, putative | 0.0065 | 0.0277 | 0.5 |
Leishmania major | fk506-binding protein 1-like protein | 0.0065 | 0.0277 | 0.5 |
Giardia lamblia | FKBP-type peptidyl-prolyl cis-trans isomerase | 0.0065 | 0.0277 | 0.5 |
Loa Loa (eye worm) | Carm1-pending protein | 0.038 | 1 | 1 |
Trypanosoma brucei | peptidyl-prolyl cis-trans isomerase, putative | 0.0065 | 0.0277 | 0.5 |
Trypanosoma cruzi | peptidyl-prolyl cis-trans isomerase, putative | 0.0065 | 0.0277 | 0.5 |
Trypanosoma brucei | FK506-binding protein (FKBP)-type peptidyl-prolyl isomerase, putative | 0.0065 | 0.0277 | 0.5 |
Plasmodium falciparum | peptidyl-prolyl cis-trans isomerase FKBP35 | 0.0065 | 0.0277 | 0.5 |
Leishmania major | peptidylprolyl isomerase-like protein | 0.0065 | 0.0277 | 0.5 |
Echinococcus multilocularis | histone arginine methyltransferase CARMER | 0.038 | 1 | 1 |
Toxoplasma gondii | histone arginine methyltransferase PRMT4/CARM1 | 0.038 | 1 | 0.5 |
Schistosoma mansoni | immunophilin | 0.0065 | 0.0277 | 0.0277 |
Schistosoma mansoni | protein arginine n-methyltransferase | 0.038 | 1 | 1 |
Onchocerca volvulus | 0.0346 | 0.8945 | 0.5 | |
Echinococcus granulosus | histone arginine methyltransferase CARMER | 0.038 | 1 | 1 |
Entamoeba histolytica | peptidyl-prolyl cis-trans isomerase, FKBP-type , putative | 0.0065 | 0.0277 | 0.5 |
Plasmodium vivax | 70 kDa peptidylprolyl isomerase, putative | 0.0065 | 0.0277 | 0.5 |
Mycobacterium ulcerans | FK-506 binding protein, peptidyl-prolyl cis-trans isomerase | 0.0065 | 0.0277 | 0.5 |
Giardia lamblia | 70 kDa peptidylprolyl isomerase, putative | 0.0065 | 0.0277 | 0.5 |
Trichomonas vaginalis | fk506-binding protein, putative | 0.0065 | 0.0277 | 0.5 |
Echinococcus multilocularis | peptidyl prolyl cis trans isomerase FKBP4 | 0.0065 | 0.0277 | 0.0277 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (binding) | = 22 nM | Binding affinity of the compound for FK506 binding protein 12 using [3H]-dihydro FK-506 radioligand was determined | ChEMBL. | 9873523 |
EC50 (binding) | = 22 nM | Binding affinity of the compound for FK506 binding protein 12 using [3H]-dihydro FK-506 radioligand was determined | ChEMBL. | 9873523 |
ED50 (functional) | = 1.4 MPK | Immunosuppressive activity was determined by ex vivo murine-based model of immunosuppression, compound was administered intravenously in mouse. | ChEMBL. | 9873523 |
ED50 (functional) | = 1.4 MPK | Immunosuppressive activity was determined by ex vivo murine-based model of immunosuppression, compound was administered intravenously in mouse. | ChEMBL. | 9873523 |
ED50 (functional) | = 11.8 MPK | Neurotoxic activity was determined by measuring compound-induced hypothermia in BALB/c mice,after administering intravenously in mouse. | ChEMBL. | 9873523 |
ED50 (functional) | = 11.8 MPK | Neurotoxic activity was determined by measuring compound-induced hypothermia in BALB/c mice,after administering intravenously in mouse. | ChEMBL. | 9873523 |
ED50 (functional) | = 15 MPK | Immunosuppressive activity was determined by ex vivo murine-based model of immunosuppression, compound was administered perorally in mouse. | ChEMBL. | 9873523 |
ED50 (functional) | = 15 MPK | Immunosuppressive activity was determined by ex vivo murine-based model of immunosuppression, compound was administered perorally in mouse. | ChEMBL. | 9873523 |
IC50 (functional) | = 0.8 nM | Immunosuppressive activity was determined as the ability to inhibit T cell proliferation. | ChEMBL. | 9873523 |
Therapeutic index (ADMET) | = 8.4 | Therapeutic index was determined as mouse hypothermia ED50/murine ex vivo ED50 | ChEMBL. | 9873523 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.